IRX5's Influence on Macrophage Polarization and Outcome in Papillary Thyroid Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Jun 13

PMID 38868535

Authors

Lu Qin

Cheng Chen

Zhengwei Gui

Yun Jiang

Affiliations

Soon will be listed here.

Abstract

Background: With a rise in recent years, thyroid cancer (TC) is the most prevalent hormonal cancer worldwide. It is essential to investigate the inherent variability at the molecular level and the immune environment within tumors of various thyroid cancer subtypes in order to identify potential targets for therapy and provide precise treatment for patients with thyroid adenocarcinoma.

Methods: First, we analyzed the expression of IRX5 in pan-cancer and papillary thyroid carcinoma by bioinformatics methods and collected paired samples from our center for validation. Subsequently, we analyzed the significance of IRX5 on the prognosis and diagnosis of PTC. Next, we explored the possible mechanisms by which IRX5 affects the prognosis of thyroid cancer patients by GO/KEGG enrichment analysis, and further investigated the effect of IRX5 on immune infiltration of thyroid cancer. Ultimately, by conducting experiments on cells and animals, we were able to show how IRX5 impacts the aggressive characteristics of thyroid cancer cells and its influence on macrophages within the immune system of thyroid cancer.

Results: In 11 malignant tumors, including PTC, IRX5 is overexpressed and associated with a poor prognosis. IRX5 may affect the prognosis of PTC through embryonic organ development, ossification, mesenchyme development, etc. Increased IRX5 expression decreases the presence of cytotoxic and Th17 cells in papillary thyroid cancer. IRX5 was highly expressed in different PTC cell lines, such as K-1 and TPC-1. Silencing IRX5 effectively halted the growth and movement of PTC cells while also decreasing M2 polarization and enhancing M1 polarization in tumor-associated macrophages.

Conclusion: IRX5 could impact the outlook of individuals with PTC by stimulating the shift of macrophages to M2 in the immune surroundings of thyroid cancer growths, suggesting a potential new focus for treating thyroid cancer, particularly through immunotherapy.

Citing Articles

Thyroid Cancer-The Tumor Immune Microenvironment (TIME) over Time and Space.

Jaume J Cancers (Basel). 2025; 17(5).

PMID: 40075642 PMC: 11899416. DOI: 10.3390/cancers17050794.

The Application of microRNAs in Papillary Thyroid Cancer: A Bibliometric and Visualized Analysis.

Zhang T, Yuan B, Yu S Int J Gen Med. 2024; 17:4681-4699.

PMID: 39429957 PMC: 11490214. DOI: 10.2147/IJGM.S487239.

References

Wei X, Wang X, Xiong J, Li C, Liao Y, Zhu Y . Risk and Prognostic Factors for BRAF Mutations in Papillary Thyroid Carcinoma. Biomed Res Int. 2022; 2022:9959649. PMC: 9132653. DOI: 10.1155/2022/9959649. View

Zhang C, Gu X, Pan M, Yuan Q, Cheng H . Senescent thyroid tumor cells promote their migration by inducing the polarization of M2-like macrophages. Clin Transl Oncol. 2021; 23(6):1253-1261. DOI: 10.1007/s12094-020-02516-2. View

Lv J, Feng Z, Chen F, Liu C, Jia L, Liu P . M2-like tumor-associated macrophages-secreted Wnt1 and Wnt3a promotes dedifferentiation and metastasis via activating β-catenin pathway in thyroid cancer. Mol Carcinog. 2020; 60(1):25-37. DOI: 10.1002/mc.23268. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Muranski P, Borman Z, Kerkar S, Klebanoff C, Ji Y, Sanchez-Perez L . Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity. 2011; 35(6):972-85. PMC: 3246082. DOI: 10.1016/j.immuni.2011.09.019. View

Lei X, Lei Y, Li J, Du W, Li R, Yang J . Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy. Cancer Lett. 2019; 470:126-133. DOI: 10.1016/j.canlet.2019.11.009. View

Lewis C, Harney A, Pollard J . The Multifaceted Role of Perivascular Macrophages in Tumors. Cancer Cell. 2016; 30(2):365. DOI: 10.1016/j.ccell.2016.07.009. View

Yang X, Pappu B, Nurieva R, Akimzhanov A, Kang H, Chung Y . T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity. 2008; 28(1):29-39. PMC: 2587175. DOI: 10.1016/j.immuni.2007.11.016. View

Burman K, Wartofsky L . CLINICAL PRACTICE. Thyroid Nodules. N Engl J Med. 2015; 373(24):2347-56. DOI: 10.1056/NEJMcp1415786. View

10.

Zhang D, Qu L, Ma L, Zhou Y, Wang G, Zhao X . Genome-wide identification of transcription factors that are critical to non-small cell lung cancer. Cancer Lett. 2018; 434:132-143. DOI: 10.1016/j.canlet.2018.07.020. View

11.

Song M, Sun W, Liu Q, Wang Z, Zhang H . Global scientific trends on thyroid disease in early 21st century: a bibliometric and visualized analysis. Front Endocrinol (Lausanne). 2024; 14:1306232. PMC: 10829784. DOI: 10.3389/fendo.2023.1306232. View

12.

Hori S . Developmental plasticity of Foxp3+ regulatory T cells. Curr Opin Immunol. 2010; 22(5):575-82. DOI: 10.1016/j.coi.2010.08.004. View

13.

Schuijs M, Png S, Richard A, Tsyben A, Hamm G, Stockis J . ILC2-driven innate immune checkpoint mechanism antagonizes NK cell antimetastatic function in the lung. Nat Immunol. 2020; 21(9):998-1009. PMC: 7116357. DOI: 10.1038/s41590-020-0745-y. View

14.

Martin-Orozco N, Muranski P, Chung Y, Yang X, Yamazaki T, Lu S . T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity. 2009; 31(5):787-98. PMC: 2787786. DOI: 10.1016/j.immuni.2009.09.014. View

15.

Gomez-Skarmeta J, Modolell J . Iroquois genes: genomic organization and function in vertebrate neural development. Curr Opin Genet Dev. 2002; 12(4):403-8. DOI: 10.1016/s0959-437x(02)00317-9. View

16.

Okabe Y, Medzhitov R . Tissue-specific signals control reversible program of localization and functional polarization of macrophages. Cell. 2014; 157(4):832-44. PMC: 4137874. DOI: 10.1016/j.cell.2014.04.016. View

17.

de Palma M, Mazzieri R, Politi L, Pucci F, Zonari E, Sitia G . Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell. 2008; 14(4):299-311. DOI: 10.1016/j.ccr.2008.09.004. View

18.

Chen Y, Song Y, Du W, Gong L, Chang H, Zou Z . Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Sci. 2019; 26(1):78. PMC: 6800990. DOI: 10.1186/s12929-019-0568-z. View

19.

Li F, Ulrich M, Jonas M, Stone I, Linares G, Zhang X . Tumor-Associated Macrophages Can Contribute to Antitumor Activity through FcγR-Mediated Processing of Antibody-Drug Conjugates. Mol Cancer Ther. 2017; 16(7):1347-1354. DOI: 10.1158/1535-7163.MCT-17-0019. View

20.

Lee S, Kivimae S, Dolor A, Szoka F . Macrophage-based cell therapies: The long and winding road. J Control Release. 2016; 240:527-540. PMC: 5064880. DOI: 10.1016/j.jconrel.2016.07.018. View